20-01-2012 16:12 A conversation Dr. CC King, Ph.D., Associate Research Scientist at the UC, San Diego Pediatric Diabetes Research Center, about his work on stem cell therapy for type 1 (and type 2) diabetes.
Go here to read the rest:
Stem Cell Therapy for Type 1 Diabetes (UCSD, PDRC) - Video
12-10-2011 09:59 Stem cell therapy done at neurogen brain and spine institute pvt ltd. http://www.neurogen.in Tell: +91 9920 200 400 , 022 25281610 , 022 25283706
See the original post here:
Stem Cell Therapy for Spinal Cord Injury, India Mumbai - Video
11-01-2012 23:04 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis.
Originally posted here:
Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial - Video
23-11-2011 02:11 For instance, neural cells in the brain and spinal cord that have been damaged can be replaced by stem cells. In the treatment of cancer, cells partially damaged by radiation or chemotherapy can be replaced with new healthy stem cells that adapt to the affected area, whether it be part of the brain, heart, liver, lungs, or wherever. Dead cells of almost any kind, no matter the type of injury or disease, can be replaced with new healthy cells thanks to the amazing flexibility of stem cells.
Follow this link:
Stem Cells Treatment for Spinal Cord Injuries, Successfully Results, Stem Therapy - Video
31-01-2012 21:38 http://www.StemCellTreatment.org Jaime Chiriboga was an active adult and ended up in a motorcycle accident and left a quadriplegic. Before receiving stem cell treatment he could not move his limbs. After his stem cell therapy he was able to move his limbs and got back almost 100% sensitivity in his body! We are very happy with the results and even more important Jaime is happy with his results! Please look at our website for more information!
Read the original post:
Stem Cell Treatment Paraplegic - Video
LOS ANGELES, CA--(Marketwire -02/02/12)- PHI Group, Inc. (OTCQB: PHIE.PK - News) (Pinksheets: PHIE.PK - News) announced today that Humex Medical Group, Inc. has signed an agreement with Tri Phuoc Co., Ltd, a Vietnamese company, to establish a stem cell center in Vietnam.
According to the agreement, Tri Phuoc will provide the required investment capital and Humex will supply the stem cell technologies to set up and operate a stem cell research and cosmetic surgery center in Ho Chi Minh City, Vietnam. Humex will be entitled to 60% of the anticipated profits from the center's operations.
Provimex, Inc., previously a majority-owned subsidiary of PHI Group, which has merged with Humex Medical Group, will complete its financial audits in conjunction with Humex's and file a registration statement with the Securities and Exchange Commission to become a fully reporting public company focused on stem cell research and therapies. PHI Group and its shareholders currently retain a minority interest in the combined company.
Eric Jeong, President of Humex, said, "We are pleased to partner with Tri Phuoc to establish the first stem cell research center of its kind in Vietnam to provide treatment for various diseases using advanced stem cell technologies."
About Humex Medical and Provimex
A wholly-owned subsidiary of Provimex, Inc., Humex Medical Group has been engaged in cosmetic surgeries, anti-aging and regenerative treatments. Provimex plans to go public by filing a registration statement with the SEC and will focus on stem cell research, stem cell therapeutics, stem cell-based cosmetics and adult stem cell banking services.
About PHI Group
PHI Group, Inc. focuses on energy and natural resources in Southeast Asia and holds majority interests in subsidiaries engaged in real estate development and M&A consulting services. In addition, it also holds minority interests in other companies such as Provimex. Website: http://www.phiglobal.com.
Safe Harbor: This news release and the featured interview contain forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. Such forward-looking statements are made based upon management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Go here to read the rest:
Humex Medical Signs Agreement to Establish Stem Cell Center in Vietnam
27-01-2012 09:54
Read the rest here:
Stem Cell Therapy for Arthritis Osteoarthritis Treatment new - Video
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn™ technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Melamed and Professor Offen of the Tel Aviv University.
In these studies, bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF), from patients with Huntington’s disease, were transplanted into the animal model of this disease and showed therapeutic improvement.
“The findings from this study demonstrate that stem cells derived from patients with a neurodegenerative disease, which are processed using BrainStorm’s NurOwn™ technology, may alleviate neurotoxic signs, in a similar way to cells derived from healthy donors. This is an important development for the company, as it confirms that autologous transplantation may be beneficial for such additional therapeutic indications,” said Dr. Adrian Harel, BrainStorm’s CEO.
"These findings provide support once again that BrainStorm’s MSC-NTF secreting cells have the potential to become a platform that in the future will provide treatment for various neuro-degenerative diseases," says Chaim Lebovits, President of BrainStorm. "This study follows previously published pre-clinical studies that demonstrated improvement in animal models of neurodegenerative diseases such as Parkinson’s, Multiple Sclerosis (MS) and neural damage such as optic nerve transection and sciatic nerve injury. Therefore, BrainStorm will consider focusing on a new indication in the near future, in addition to the ongoing Clinical Trials in ALS.”
BrainStrom is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results from the clinical trial (which is designed mainly to test the safety of the treatment), that were announced last week, have shown that the Brainstorm’s NurOwn™ therapy is safe and does not show any significant treatment-related adverse events and have also shown certain signs of beneficial clinical effects.
To read the Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. please go to:
http://www.sciencedirect.com/science/article/pii/S0014488612000295
About BrainStorm Cell Therapeutics, Inc.
BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.
Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.
Read this article:
Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's ...
Pro/Am ballroom dancer and orthodontist, Dr. Janet Vaughan, is once again slated to compete on the professional dance circuit with her current professional partner, Mr. Eddie Stutts (Professional 10-Dance World Champion) following a successful stem cell procedure on her knee in Panama.
Corpus Christi, TX (PRWEB) February 01, 2012
Pro/Am ballroom dancer and orthodontist, Dr. Janet Vaughan, is once again slated to compete on the professional dance circuit with her current professional partner, Mr. Eddie Stutts (Professional 10-Dance World Champion) following a successful stem cell procedure on her knee in Panama.
From 2007-2009, Dr. Vaughan partnered with World Champion Tony Dovolani and competed extensively in the U.S., winning a National Reserve Pro/Am Rhythm title. Tony Dovolani is best known for his appearances on ABC's hit reality series, "Dancing with the Stars", and has teamed up with Chynna Phillips, Wendy Williams, Audrina Partridge, Kate Gosselin, Kathy Ireland, Susan Lucci, Jane Seymour and other celebrities on the show.
Dr. Vaughan and Mr. Stutts are slated to compete in the Heritage Classic Dancesport Championships in Asheville, North Carolina next month. This will be the first time Dr. Vaughan has been able to compete since 2010 when she sustained a dancing related knee injury.
Dr. Vaughan also suffered from chronic neck pain resulting from injuries sustained in a car crash twenty years ago. Her neck injury culminated in a natural fusion of the c5-c6 vertebrae, scoliosis and extreme pain when her neck slipped out of alignment.
In an attempt to repair her knee and get her dancing career back on track, Dr. Vaughan decided to undergo stem cell therapy at the Stem Cell Institute in Panama City, Panama. "I was basically removed from competitive dance work because I could not rise or squat without extreme pain. I had also resigned myself to enduring chronic neck pain from my past accident and painful hand joints due to generalized arthritis," said Dr. Vaughan.
Dr. Vaughan 's knee was treated with stem cells that were harvested from her own adipose (fat) tissue.
The fat tissue sample is collected via mini-liposuction, which is performed by a certified plastic surgeon under light, general anesthesia. Mesenchymal stem cells and T regulatory cells reside within this tissue.
Adipose-derived cells are then separated from the fat at Medistem Panama’s state-of-the-art laboratory at the prestigious City of Knowledge. This entire process is subjected to stringent quality control. Before they can be administered back into the patient, these adipose-derived stem cells are tested for quality, bacterial contamination (aerobic and anaerobic) and endotoxin.
All patients treated with adipose stem cells at the Stem Cell Institute wait about one week before the stem cells can be re-implanted to minimize the probability of the cells migrating back to the liposuction injury site. This essential procedural step separates treatment in Panama from "same-day" protocols offered elsewhere.
The adipose-derived stem cells are administered by a highly-qualified physician into the affected joint(s) (intra-articular injection) and intravenously (IV).
"It's taken about 6 months but I am amazed at the results I've gotten with my knee. Even my neck is better. I used to spend almost $1,000 per month on a neuromuscular massage therapist but I haven't needed any neuromuscular massages for the past 6 months. I wasn't counting on that. Even my doctors say that the dense scar tissue in my neck has changed in texture from grizzly to smooth, supple tissue," exclaimed Dr. Vaughan.
She continued, "I just danced 6 hours in Houston preparing for the upcoming competition in Asheville and my knee isn't even sore."
Dr. Vaughan is planning to return to Panama for a follow-up treatment this summer.
About the Stem Cell Institute
Founded in 2006 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, the institute’s doctors treat carefully selected patients with spinal cord injury, osteoarthritis, heart disease, multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases. Doctors at The Stem Cell Institute have treated over 1000 patients to-date.
About Medistem Panama Inc.
Medistem performs all stem cell processing for the Stem Cell Institute. It operates an 8000 sq. ft. cGMP and cGMP compliant laboratory that features 3 class 10000 clean rooms, 8 class 100 laminar flow hoods, and 12 class 100 incubators.
For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com
Stem Cell Institute
Via Israel & Calle 66
Pacifica Plaza Office #2A
San Francisco, Panama
Republic of Panama
Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)
Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)
###
Jay Lenner
jdlenner@cellmedicine.com
1-800-980-7836
Email Information
View post:
Pro/Am Dancer is "Dancing with the Stars" Again After Stem Cell Therapy in Panama
WEDNESDAY, Feb. 1 (HealthDay News) -- Treating stroke patients with stem cells taken from their own bone marrow appears to safely help them regain some of their lost abilities, two small new studies suggest.
Indian researchers observed mixed results in the extent of stroke patients' improvements, with one study showing marked gains in daily activities, such as feeding, dressing and movement, and the other study noting these improvements to be statistically insignificant. But patients seemed to safely tolerate the treatments in both experiments with no ill effects, study authors said.
"The results are encouraging to know but we need a larger, randomized study for more definitive conclusions," said Dr. Rohit Bhatia, a professor of neurology at the All India Institute of Medical Sciences in New Delhi, and author of one of the studies. "Many questions -- like timing of transplantation, type of cells, mode of transplantation, dosage [and] long-term safety -- need answers before it can be taken from bench to bedside."
The studies are scheduled to be presented Wednesday and Thursday at the American Stroke Association's annual meeting in New Orleans.
Stem cells -- unspecialized cells from bone marrow, umbilical cord blood or human embryos that can change into cells with specific functions -- have been explored as potential therapies for a host of diseases and conditions, including cancer and strokes.
In one of the current studies, 120 moderately affected stroke patients ranging from 18 to 75 years old were split into two groups, with half infused intravenously with stem cells harvested from their hip bones and half serving as controls. About 73 percent of the stem cell group achieved "assisted independence" after six months, compared with 61 percent of the control group, but the difference wasn't considered statistically significant.
In the other study, presented by Bhatia, 40 patients whose stroke occurred between three and 12 months prior were also split into two groups, with half receiving stem cells, which were dissolved in saline and infused over several hours. When compared to controls, stroke patients receiving stem cell therapy showed statistically significant improvements in feeding, dressing and mobility, according to the study. On functional MRI scans, the stem cell recipients also demonstrated an increase in brain activity in regions that control movement planning and motor function.
Neither study yielded adverse effects on patients, which could include tumor development.
But Dr. Matthew Fink, chief of the division of stroke and critical care neurology at New York-Presbyterian Hospital/Weill Cornell Medical Center, said that the therapy's safety is the only thing the two studies seemed to demonstrate.
"The thing to keep in mind is that these are really phase one trials," said Fink, also a professor of neurology at Weill Cornell Medical College. "I'm concerned that people get the idea that now stem cell treatment is available for stroke, and that's not the case."
Fink noted that the cells taken from study participants' hip bones can only be characterized as "bone marrow aspirates" since the authors didn't prove that actual stem cells were extracted.
"They haven't really analyzed if they're stem cells and what they turn into when they go into circulation," he added. "The best way to look at this is, it's very preliminary . . . when patients come to me to talk about it, I'm going to tell them it's years away before we know if this is going to work."
Studies presented at scientific conferences should be considered preliminary until published in a peer-reviewed medical journal.
More information
The U.S. National Institutes of Health has more information on stem cells.
Read the original:
Stem Cell Therapy Shows Promise for Stroke, Studies Say